Lineage Cell Therapeutics (LCTX) Cash from Investing Activities (2010 - 2026)

Lineage Cell Therapeutics has reported Cash from Investing Activities for 17 years, with the latest figure at -$2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 222.23% year-over-year to -$2.3 million; the trailing twelve-month figure through Mar 2026 stood at -$17.7 million (down 4719.07% YoY), and the FY2025 full-year result was -$13.5 million, down 483.06% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$2.3 million, up from -$15.3 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $19.2 million in Q2 2023, with the low at -$40.9 million in Q3 2022.
• Historically, Cash from Investing Activities has averaged -$1.0 million across 5 years, with a median of -$14000.0 in 2025.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 60067.65% — and 2023, when it surged 33634.78%.
• Lineage Cell Therapeutics' Cash from Investing Activities stood at -$5.1 million in 2022, then jumped by 290.94% to $9.7 million in 2023, then plunged by 72.95% to $2.6 million in 2024, then slumped by 681.94% to -$15.3 million in 2025, then soared by 84.83% to -$2.3 million in 2026.
• The last three Cash from Investing Activities figures came in at -$2.3 million (Q1 2026), -$15.3 million (Q4 2025), and -$12000.0 (Q3 2025), per Business Quant data.